RNA Editing for Muscular Dystrophy Therapy© 2016, Springer Science+Business Media New York.Due to lack of effective therapies,
muscular Pre- and posttranscriptional genetic information modification in muscular dystrophy treatment groups of genetic pathologies is musculardystrophy, including such diseases as Duchenne
muscular RNA Editing for Muscular Dystrophy Therapy© 2016, Springer Science+Business Media New York.Due to lack of effective therapies,
muscular Pre- and posttranscriptional genetic information modification in muscular dystrophy treatment groups of genetic pathologies is musculardystrophy, including such diseases as Duchenne
muscular Modeling and gene therapy of dysferlinopathy-girdle
Muscular Dystrophy type 2B (LGMD2B) and distal myopathy with anterior tibial onset. Also, dysferlin
Modeling and gene therapy of dysferlinopathy-girdle
Muscular Dystrophy type 2B (LGMD2B) and distal myopathy with anterior tibial onset. Also, dysferlin
Twenty-year clinical progression of dysferlinopathy in patients from DagestanUmakhanova Z.,
Bardakov S.,
Mavlikeev M.,
Chernova O.,
Magomedova R.,
Akhmedova P.,
Yakovlev I.,
Dalgatov G.,
Fedotov V.,
Isaev A.,
Deev R. , Fedotov, Isaev and Deev.To date, over 30 genes with mutations causing limb-girdle muscle
dystrophy have